AMICUS THERAPEUTICS, INC. — Director's Dealing 2018

Apr 16, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMICUS THERAPEUTICS INC (FOLD)
CIK: 0001178879
Period of Report: 2018-04-12

Reporting Person: Barth Jay (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-04-12	Common Stock	M	5000	$2.29	Acquired	90409	Direct
2018-04-12	Common Stock	S	5000	$14.7204	Disposed	85409	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-04-12	Stock Options (right to buy)	$2.29	M	5000	Disposed	2024-03-03	Common Stock (5000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	125	Indirect

Footnotes

F1: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2017.

F2: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.61 to $14.86. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: All of the options were fully vested and exercisable as of April 12, 2018.